Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2018-09-01
Sarja:	Cancer Medicine
Aiheet:	eribulin metastatic breast cancer real‐world survival triple negative
Linkit:	https://doi.org/10.1002/cam4.1705
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!